News Feed

Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Topline study results expected in the first half of 2022; Biologics License Application (BLA) filing anticipated in the second half of 2022 […]